Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.
The endogenous cannabinoid receptor agonist anandamide is a powerful vasodilator of isolated vascular preparations, but its mechanism of action is unclear. Here we show that the vasodilator response to anandamide in isolated arteries is capsaicin-sensitive and accompanied by release of calcitonin-gene-related peptide (CGRP). The selective CGRP-receptor antagonist 8-37 CGRP, but not the cannabinoid CB1 receptor blocker SR141716A, inhibited the vasodilator effect of anandamide. Other endogenous (2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP 55,940) CB1 and CB2 receptor agonists could not mimic the action of anandamide. The selective 'vanilloid receptor' antagonist capsazepine inhibited anandamide-induced vasodilation and release of CGRP. In patch-clamp experiments on cells expressing the cloned vanilloid receptor (VR1), anandamide induced a capsazepine-sensitive current in whole cells and isolated membrane patches. Our results indicate that anandamide induces vasodilation by activating vanilloid receptors on perivascular sensory nerves and causing release of CGRP. The vanilloid receptor may thus be another molecular target for endogenous anandamide, besides cannabinoid receptors, in the nervous and cardiovascular systems.
Zygmunt
P M
PM
Department of Clinical Pharmacology, Institute of Laboratory Medicine, University of Lund, Sweden.
Petersson
J
J
Andersson
D A
DA
Chuang
H
H
Sørgård
M
M
Di Marzo
V
V
Julius
D
D
Högestätt
E D
ED
D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D001488:Basilar Artery / Q000187:drug effects / Q000294:innervation; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism / Q000494:pharmacology; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D015220:Calcium Channels / Q000378:metabolism; D002211:Capsaicin / Q000031:analogs & derivatives / Q000494:pharmacology; D002460:Cell Line; D063388:Endocannabinoids; D005260:Female; D006168:Guinea Pigs; D006499:Hepatic Artery / Q000187:drug effects / Q000294:innervation; D066298:In Vitro Techniques; D009475:Neurons, Afferent / Q000187:drug effects / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D051381:Rats; D017208:Rats, Wistar; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D014665:Vasodilator Agents / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D014981:Xenopus
D001095:Arachidonic Acids; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D015220:Calcium Channels; C469526:Cnr2 protein, rat; D063388:Endocannabinoids; D010446:Peptide Fragments; D053284:Polyunsaturated Alkamides; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D011994:Recombinant Proteins; D014665:Vasodilator Agents; C058636:calcitonin gene-related peptide (8-37); D015740:Calcitonin Gene-Related Peptide; C071423:capsazepine; D002211:Capsaicin; C078814:anandamide